Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Medical Brands
AMSTERDAM, January 30, 2014 /PRNewswire/ --
Medical Brands has obtained a Class IIb status for it's Uninary Tract Infections Self-Care Medical Device
Based upon latest test and study reports, authorities approved the class IIb status for the Urinary Tract Infections Self-Care Medical Device developed by Medical Brands. With this status it is possible to continuously use the product, exceeding 30 days, in order to prevent Urinary Tract Infections.
Urinary tract infections (UTIs) are a serious health problem affecting millions of people each year. Today, Antibiotics are the traditional treatment for UTIs, but there is a growing global push towards other solutions as resistance to antibiotics continues to rise. The product against Urinary Tract Infections from Medical Brands is the answer for this growing demand.
As a registered Class IIb Medical Device, Cranberry-Active™ is the only cranberry-based product in the European Economic Area and recognized countries that can be freely marketed with a medical claim for treating and preventing urinary tract infections. The product is clinically proven, doesn't burden your body, works on the spot and can be used on daily basis.
Medical Brands is searching for partners to market Cranberry-Active™ bladder capsules in Europe and harmonized countries.
Note to editors
About Medical Brands
Headquartered in Amsterdam, The Netherlands, Medical Brands provides consumers with Self-care Medical Device solutions to treat and prevent everyday minor discomforts. Medical Brands develops patents, registers and provides products to treat and prevent simple every day diseases without pharmacological effects. Medical Brands markets and sells products that are registered Medical Devices.
©2012 PR Newswire. All Rights Reserved.